DGX vs MYGN
DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals. MYGN: Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions.
Side-by-side fundamentals
| Metric | DGX | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $233.01 | $2.86 | |
| Market cap as of 2026-08-03 | $25.7B | $274M | |
| P/E as of 2026-08-03 | 24.67 | n/a | |
| PEG as of 2026-08-03 | 2.61 | n/a | |
| Net margin as of 2026-08-03 | +9.2% | -14.0% | DGX higher |
| Gross margin as of 2026-08-03 | +33.2% | +68.8% | MYGN higher |
| Operating margin as of 2026-08-03 | +14.1% | -12.2% | DGX higher |
| ROE as of 2026-08-03 | +14.5% | -32.6% | DGX higher |
| ROA as of 2026-08-03 | +6.4% | -16.4% | DGX higher |
| Debt / equity as of 2026-08-03 | 0.75 | 0.40 | MYGN lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.9% | -3.2% | DGX higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | +6.7% | MYGN higher |
| Dividend yield as of 2026-08-03 | +1.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.16 | 1.05 | |
| 1-year return as of 2026-07-31 close | +39.2% | -25.5% | DGX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.